Salvato in:
| Autori principali: | , , , , , , , |
|---|---|
| Natura: | Artículo Open Access |
| Pubblicazione: |
Wiley
2026
|
| Soggetti: | |
| Accesso online: | https://onlinelibrary.wiley.com/doi/10.1002/oby.70152 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
Sommario:
- Disparities in Prescription of Long‐Acting GLP‐1s Katherine Wasden Nora Sheu Pourya Medhati Thomas C. Tsai Dong Wook Kim Ali Tavakkoli Caroline M. Apovian Eric G. Sheu Obesity ABSTRACT Objective Broadening usage of new antiobesity medications (AOMs, e.g., GLP‐1 and GLP‐1/GIP agonists) has prompted access concerns. We analyzed patient and appointment factors associated with AOM prescriptions, including changing AOM coverage in state Medicaid programs (MassHealth). Methods This was a retrospective pre‐post study of medical weight management appointments at a large tertiary care center in January and April 2024, bracketing a MassHealth coverage change for AOMs. Patient and visit characteristics and AOMs prescribed were analyzed. Results A total of 2060 patients were analyzed. Multivariable analysis demonstrated that patients were more likely to receive Sema/Tirz compared to no or a different AOM with private insurance (aOR 2.744, p < 0.001), diabetes (aOR 2.507, p < 0.001), and established patient relationships (aOR 1.706, p < 0.001). In January 2024, Black and Hispanic patients were 49% and 47% less likely to be prescribed Sema/Tirz ( p = 0.003, p = 0.025); in April 2024, after MassHealth changes, only patients of “Not Disclosed” race were less likely to receive these medications ( p < 0.001). Conclusions Black and Hispanic patients were less likely and patients with private insurance, diabetes, and established patient relationships were more likely to be prescribed Sema/Tirz. Racial and ethnic disparities in medication prescription were less apparent after a state Medicaid policy change to cover new GLP‐1s. 10.1002/oby.70152 http://onlinelibrary.wiley.com/termsAndConditions#vor